A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

Vaccine

Volumn 24, Issue 21, 2006, Pages 4677-4687

  Schadeck, Eva B ^a   Sidhu, Maninder ^a   Egan, Michael A ^a   Chong, Siew Yen ^a   Piacente, Priscilla ^a   Masood, Amjed ^a   Garcia Hand, Dorys ^a   Cappello, Sarah ^a   Roopchand, Vidia ^a   Megati, Shakuntala ^a   Quiroz, Jorge ^a   Boyer, Jean D ^b   Felber, Barbara K ^c   Pavlakis, George N ^c   Weiner, David B ^b   Eldridge, John H ^a   Israel, Zimra R ^a  

^a WYETH RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; AIDS; Cytokines; Vaccination

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12;

ARTICLE; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; MACACA; NONHUMAN; PLASMID; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, GAG; IMMUNITY, CELLULAR; INTERLEUKIN-12; MACACA MULATTA; PLASMIDS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

EID: 33646835940     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.10.035     Document Type: Article

References (41)

1. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 247 (1990) 1465-1468
2. Tang D.C., De Vit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 (1992) 152-154
3. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
4. Sedegah M., Hedstrom R., Hobart P., and Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 91 (1994) 9866-9870
5. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98 (2001) 10817-10822
6. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
7. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 (1998) 92-100
8. Boyer J.D., Chattergoon M.A., Ugen K.E., Shah A., Bennett M., Cohen A., et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol 90 (1999) 100-107
9. Boyer J.D., Cohen A.D., Vogt S., Schumann K., Nath B., Ahn L., et al. Vaccination of seronegative volunteers with a human immunodeficiency virus Type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 181 (2000) 476-483
10. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351 (1998) 1320-1325
11. Calarota S.A., Leandersson A.C., Bratt G., Hinkula J., Klinman D.M., Weinhold K.J., et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 163 (1999) 2330-2338
12. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 (2000) 1893-1901
13. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764-778
14. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., and Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17 (1999) 2826-2829
15. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M., Boyer J.D., Wang B., et al. Development of a multicomponent candidate vaccine for HIV-1. Vaccine 15 (1997) 879-883
16. Kim J.J., Nottingham L.K., Tsai A., Lee D.J., Maguire H.C., Oh J., et al. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 28 (1999) 214-223
17. Gherardi M.M., Ramirez J.C., and Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74 (2000) 6278-6286
18. Raz E., Watanabe A., Baird S.M., Eisenberg R.A., Parr T.B., Lotz M., et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci USA 90 (1993) 4523-4527
19. Gately M.K., Wilson D.E., and Wong H.L. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 136 (1986) 1274-1282
20. Robertson M.J., Soiffer R.J., Wolf S.F., Manley T.J., Donahue C., Young D., et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175 (1992) 779-788
21. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16 (1998) 365-396
22. Scott P., and Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin Immunol 9 (1997) 285-291
23. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
24. van der Meide P.H., Villinger F., Ansari A.A., Groenestein R.J., de Labie M.C.D.C., van den Hout Y.J.M., et al. Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 in Rhesus macaques. Vaccine 20 (2002) 2296-2302
25. O'Neill E., Martinez I., Villinger F., Rivera M., Gascot S., Colon C., et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol 31 (2002) 217-227
26. Hanlon L., Argyle D., Bain D., Nicolson L., Dunham S., Golder M.C., et al. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol 75 (2001) 8424-8433
27. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
28. Koblish H.K., Hunter C.A., Wysocka M., Trinchieri G., and Lee W.M.F. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (INOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 188 (1998) 1603-1610
29. Chen H.-W., Pan C.-H., Huan H.-W., Liau M.-Y., Chiang J.-R., and Tao M.-H. Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid. J Immunol 166 (2001) 7419-7426
30. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77 (2003) 2081-2092
31. Car B.D., Eng V.M., Lipman J.M., and Anderson T.D. The toxicology of interleukin-12: a review. Toxicol Pathol 27 (1999) 58-63
32. Bree A.G., Schlerman F.J., Kaviani M.D., Hastings R.C., Hitz S.L., and Goldman S.J. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 204 (1994) 1150-1157
33. Quezada A., Horner M.J., Loera D., French M., Pericle F., Johnson R., et al. Safety toxicity study of plasmid-based IL-12 therapy in Cynomolgus monkeys. J Pharm Pharmacol 54 (2002) 241-248
34. Marshall E. Cancer trial of IL-12 halted. Science 268 (1995) 1555
35. Koup R., Safrit J., Cao Y., Andrews C., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
36. Eberl G., Kessler B., Eberl L.P., Brunda M.J., Valmori D., and Corradin G. Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur J Immunol 26 (1996) 2709-2716
37. Knapp L.A., Lehmann E., Piekarczyk M.S., Urvater J.A., and Watkins D.I. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50 (1997) 657-661
38. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 66 (1992) 7176-7182
39. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 (1992) 150-159
40. Schneider R., Campbell M., Nasioulas G., Felber B., and Pavlakis G. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of gag and gag/protease and particle formation. J Virol 71 (1997) 4892-4903
41. Pachuk C.J., Ciccarelli R.B., Samuel M., Bayer M.E., Troutman R.D., Zurawski D.V., et al. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. Biochim Biophys Acta 1468 (2000) 20-30